Discover How Obagi Sets the Standard for Science-Backed Skincare
Skincare Anarchy
Ekta et al.
4.2 • 2K Ratings
🗓️ 4 October 2024
⏱️ 38 minutes
🧾️ Download transcript
Summary
In this episode, Ekta talks with Justin Giouzepis, Chief Marketing Officer of Obagi, about the brand’s long-standing impact on the skincare industry. Obagi, known for its clinically proven and science-backed skincare solutions, has earned the trust of dermatologists, plastic surgeons, and consumers worldwide. Justin shares how Obagi's commitment to efficacy and real results has set the brand apart for decades.
Justin highlights Obagi’s “trust over trends” philosophy, focusing on scientifically validated ingredients rather than fleeting beauty fads. With rigorous clinical testing and a dedication to addressing a range of skin types, Obagi remains a reliable choice for those seeking long-term skin health.
The conversation also explores Obagi’s innovation beyond skincare basics, such as its development of brow and eyelash serums, and its close collaboration with medical professionals. The brand’s *Nuderm* protocol and post-procedure products like *Rebalance* are essential for supporting skin before and after treatments like microneedling.
With an eye on global trends and continued innovation, Obagi stays true to its mission of delivering effective, trusted skincare solutions. Tune in to learn more about how Obagi maintains its leadership in the cosmeceutical space.
To learn more about Obagi and to shop their products, visit their website and social media. Don’t forget to subscribe to Skincare Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.
Hosted on Acast. See acast.com/privacy for more information.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Hey guys welcome back to Skin Anarchy this is your whole sector and I am really really excited about |
| 0:04.9 | the brand here today. I think a lot of you have heard of them. They've been around for a long time making |
| 0:09.8 | amazing products. I know quite a few people you know in my peer group that have at least one or two |
| 0:15.8 | products by the line so without further ado I want to introduce you guys to |
| 0:19.3 | chief marketing officer of Obagi Justin Giuseppe, right? |
| 0:24.0 | You Zepa, that's great. |
| 0:25.6 | You did a great job. |
| 0:26.6 | Great. |
| 0:27.6 | Welcome, Justin. |
| 0:28.6 | I'm excited to chat with you and learn from each day. |
| 0:30.6 | I'm thrilled to be here. |
| 0:32.0 | I would love to get started if you could tell us a little bit about yourself, you know, and your background and what got you involved with Obagi and maybe get us started. |
| 0:40.3 | Yeah, so you know, I've been a beauty junkie, so to speak, forever. You know, I've always been super, |
| 0:47.0 | hair, skin, cosmetics involved. You know, I was like tinkering around in my grandmother's bathroom at six. |
| 0:54.7 | So this is absolutely, you know, the category I love. |
| 1:00.1 | You know, I love science-backed categories, and I've worked in both skin and hair color, which are chemistry-based. |
| 1:07.0 | And it's always been important to me. |
| 1:09.0 | So I started my beauty career at a beauty giant, we know names L'Oreal and I worked across |
| 1:16.2 | several brands and divisions and countries. |
| 1:18.8 | I also have worked in body care at Henkel which was very skin focused and all about skin health all the way |
| 1:26.1 | from, you know, antibacterial soaps into moisturizing body washes. |
| 1:31.1 | And then I had the good fortune of meeting our founders of Waldencast who had recently |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Ekta et al., and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Ekta et al. and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.